View Future GrowthMonash IVF Group 過去の業績過去 基準チェック /26Monash IVF Groupの収益は年間平均-15%の割合で減少していますが、 Healthcare業界の収益は年間 増加しています。収益は年間12.2% 12.1%割合で 増加しています。 Monash IVF Groupの自己資本利益率は10.3%であり、純利益率は9.2%です。主要情報-15.04%収益成長率-18.46%EPS成長率Healthcare 業界の成長8.50%収益成長率12.06%株主資本利益率10.25%ネット・マージン9.20%前回の決算情報30 Jun 2025最近の業績更新お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026すべての更新を表示Recent updatesお知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.お知らせ • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australiaお知らせ • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.お知らせ • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.収支内訳Monash IVF Group の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MNIV.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費30 Jun 252722524031 Mar 252711122031 Dec 24270-221030 Sep 24263-421030 Jun 24255-721031 Mar 24246920031 Dec 232362420030 Sep 232252319030 Jun 232142218031 Mar 232041918031 Dec 221951718030 Sep 221931818030 Jun 221921818031 Mar 221932118031 Dec 211942317030 Sep 211892416030 Jun 211842514031 Mar 211712213031 Dec 201591813030 Sep 201521512030 Jun 201451212031 Mar 201491512031 Dec 191521812030 Sep 191521912030 Jun 191522011031 Mar 191511914031 Dec 181511917030 Sep 181512017030 Jun 181512117031 Mar 181522417031 Dec 171532616030 Sep 171542816030 Jun 171553016031 Mar 171563016031 Dec 161563015030 Sep 161562916030 Jun 161572916031 Mar 161502713031 Dec 15144249030 Sep 15134239030 Jun 15125219031 Mar 15121158031 Dec 1411788030 Sep 14115580質の高い収益: MNIV.Fは 高品質の収益 を持っています。利益率の向上: MNIV.F過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MNIV.Fの収益は過去 5 年間で年間15%減少しました。成長の加速: MNIV.Fは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: MNIV.F昨年収益を上げたため、昨年の収益成長をHealthcare業界 ( 17.3% ) と比較することは困難です。株主資本利益率高いROE: MNIV.Fの 自己資本利益率 ( 10.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YHealthcare 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/09/06 15:02終値2025/06/10 00:00収益2025/06/30年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Monash IVF Group Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15 アナリスト機関Martyn JacobsBell PotterTara SperanzaBell PotterBradley WatsonBell Potter12 その他のアナリストを表示
お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
お知らせ • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
お知らせ • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
お知らせ • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
お知らせ • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
お知らせ • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
お知らせ • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia
お知らせ • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.
お知らせ • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.